Skip to main content
H.R. 9358 117th Congress House

Access to Innovative Treatments Act of 2022

Official title: To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.

Introduced: November 29, 2022 Introduced by: Nanette Diaz Barragán Democratic · California See on congress.gov
Health
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 30, 2022
Referred to the Subcommittee on Health.
Nov 29, 2022
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Nov 29, 2022
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action November 30, 2022

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Access to Innovative Treatments Act of 2022

This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. (Under the bill, adverse national coverage determinations are denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration.) The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.

The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

 Related & companion bills 1
  • HR 2408 Reintroduced Bill Access to Innovative Treatments Act of 2023
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 3
 Cosponsors 1
All 1 Republican 1
R
Joyce, John
Pennsylvania · Nov 29, 2022
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 9358: Access to Innovative Treatments Act of 2022. 117th Congress. Open America. https://openamerica.io/bill/117-HR-9358/
MLA
"H.R. 9358: Access to Innovative Treatments Act of 2022." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-9358/.
Bluebook (legal)
H.R. 9358, 117th Cong. (2026), https://openamerica.io/bill/117-HR-9358/.
Markdown link
[H.R. 9358: Access to Innovative Treatments Act of 2022](https://openamerica.io/bill/117-HR-9358/)
Report a problem